Ceftibuten sustained release tablets

A technology of ceftibuten and sustained-release tablets, which is applied in the new field of medicine, can solve problems such as inconvenience, and achieve the effects of high quality, simple method, and reduction of adverse drug reactions

Inactive Publication Date: 2009-07-01
BEIJING HOPE HUGE PHARM SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the third-generation varieties need to be administered by injection, which is very inconvenient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ceftibuten sustained release tablets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1: specification 1000 pieces

[0030] prescription:

[0031] Ceftibuten 400g

[0032] Microcrystalline Cellulose 90g

[0033] Stearic acid 80g

[0034] Ethyl cellulose 50g

[0035] Macrogol 4000 20g

[0036] Eudragit RS 100 50g

[0037] Silica 3g

[0038] Magnesium Stearate 2g

[0039] Ethanol 50ml

[0040] Preparation method:

[0041] After dissolving the prescribed amount of ethyl cellulose with ethanol, add Eudragit RS 100 and Polyethylene Glycol 4000 to dissolve for later use, pass the prescribed amount of ceftibuten through a 100 mesh sieve and mix it with the prescribed amount of microcrystalline cellulose and stearic acid Evenly, add the above solution while stirring, make soft material, pass through 18 mesh sieve to granulate, dry, add prescription amount of magnesium stearate and silicon dioxide, pass through 20 mesh sieve for granulation, mix evenly, measure the content of intermediates , after passing the test, the tablet is pressed, and ...

Embodiment 2

[0042] Embodiment 2: specification 10000 pieces

[0043] prescription:

[0044] Ceftibuten 4000g

[0045] Microcrystalline Cellulose 900g

[0046] Stearic acid 800g

[0047] Ethyl cellulose 500g

[0048] Macrogol 4000 200g

[0049] Eudragit RS 100 500g

[0050] Silica 30g

[0051] Magnesium Stearate 20g

[0052] Ethanol 550ml

[0053] Preparation method:

[0054] After dissolving the prescribed amount of ethyl cellulose with ethanol, add Eudragit RS 100 and Polyethylene Glycol 4000 to dissolve for later use, pass the prescribed amount of ceftibuten through a 100 mesh sieve and mix it with the prescribed amount of microcrystalline cellulose and stearic acid Evenly, add the above solution while stirring, make soft material, pass through 18 mesh sieve to granulate, dry, add prescription amount of magnesium stearate and silicon dioxide, pass through 20 mesh sieve for granulation, mix evenly, measure the content of intermediates , after passing the test, the tablet is pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the novel technology field of the medicines and relates to a novel dosage form of ceftibuten for treating: upper respiratory tract infection such as pharyngitis, antiaditis, scarlet fever, paranasal sinusitis, and otitis medium; lower respiratory tract infection such as acute bronchitis, acute attack of chronic bronchitis and pneumonia; urinary tract infection; enteritis and gastroenteritis. The novel dosage form is characterized in that the dosage form is sustained-release tablets and can release medicines in a low and unsteady speed in water or specified release medium. The sustained-release tablets of the invention can make the medicines reach a steady blood-drug concentration level in vivo through releasing slowly, decrease adverse drug reaction and reduce the generation of drug-resistant strain.

Description

technical field [0001] The invention belongs to the field of new medicine technology, and relates to a new dosage form of ceftibuten, which is used for treating upper respiratory tract infections such as pharyngitis, tonsillitis, scarlet fever, paranasal sinusitis and otitis media; lower respiratory tract infections such as acute bronchitis and acute chronic bronchitis seizures, pneumonia; urinary tract infection; enteritis and gastroenteritis. Specifically, it is a ceftibuten sustained-release tablet. Background technique [0002] Ceftibuten (Ceftibuten) is the third-generation broad-spectrum oral cephalosporin created by Japan Shionogi Company, chemical name: (+)-(6R,7R)-7-[(Z)-2-(2-amino -4-thiazole)-4carboxy-crotonamide]-8-oxo-5-thio-1-nitrobicyclo[4,2,0]oct-2-ene-2-carboxylic acid dihydrate. [0003] Ceftibuten, also known as cefotaxime and ceftibuten, is a semi-synthetic third-generation oral cephalosporin antibiotic with strong antibacterial activity. This product ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/546A61K9/22A61K47/38A61P1/00A61P31/04A61P11/00A61P11/02A61P11/04A61P13/00A61P27/16
Inventor 王翰斌闫艳立吴广俣
Owner BEIJING HOPE HUGE PHARM SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap